News
The Next Stop for AI-Powered Drug Development | Chia Tai Tianqing Partners with Revvity to Create the X-Lab Joint Shared Laboratory
Release Date: 2026-10-29
On October 28, Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 01177.HK), and Revvity, a global life sciences and diagnostics company, signed a joint shared laboratory cooperation agreement at the Shanghai Global R&D Headquarters, jointly unveiling the X-Lab automated laboratory for antibody drug R&D. X-Lab conducts cutting-edge antibody drug R&D using an intelligent, high-throughput dry-wet lab loop model, helping the group strengthen its source innovation capabilities and improve new drug R&D efficiency. It is also an intelligent experimental platform open and shared with the biopharmaceutical industry. The official unveiling of X-Lab is also a significant step forward in advancing the construction of cutting-edge R&D infrastructure and gathering international innovation resources since the launch of the Chia Tai Tianqing Global R&D Headquarters.
![]()
Building an Intelligent Antibody Drug R&D Platform
On June 6 this year, the Chia Tai Tianqing Global R&D Headquarters, with a total investment of 1.8 billion RMB, was officially launched in Shanghai's Hongqiao Qianwan, dedicated to creating a global hub for innovative biopharmaceutical R&D and translation. Leveraging global R&D resources and its industrial foundation, the Chia Tai Tianqing Global R&D Headquarters is advancing the construction of an interdisciplinary and cross-industry innovation incubation park to promote the synergistic development of cutting-edge technology R&D, results translation, and industrial incubation.
X-Lab is the first open experimental platform to be implemented in this layout. It has established a plasmid transfection platform and an antibody affinity screening platform, and is equipped with a central intelligent control system to promote the systematic integration of experimental processes, equipment operation, and data collection, enhancing the high-throughput screening and intelligent validation capabilities for early antibody drug discovery.
Among them, the plasmid transfection platform is set up in a clean cell room and is responsible for cell culture, antibody expression, and related sample preparation. The antibody affinity screening platform integrates technologies such as ELISA testing, flow cytometry, and molecular interaction analysis, enabling precise screening of superior candidate molecules with high affinity and high efficacy. It also supports different testing scenarios and can autonomously execute differentiated experimental procedures. The two platforms rely on the central intelligent control system to achieve unified cross-platform scheduling and collaborative operations via automated guided vehicles (AGVs) and automated pass-through windows.
Creating an Open and Shared Carrier for Industrial Innovation
![]()
![]()
Currently, the biopharmaceutical industry is accelerating its move towards open innovation. It has become difficult for a single enterprise to cover all cutting-edge technologies, making open collaboration an industry imperative. Relying on its Global R&D Headquarters, Chia Tai Tianqing is advancing the construction of a grand open innovation center. The X-Lab, an automated shared laboratory for antibody drug R&D open to the industry, was created as a result, and a joint shared laboratory cooperation with Revvity was successfully established.
X-Lab is open to universities, research institutes, biotechnology companies, and startup teams, providing R&D support such as antibody expression, screening and evaluation, and functional validation, thereby lowering the resource and technology barriers for early-stage R&D. The joint laboratory leverages Chia Tai Tianqing's new drug R&D pipeline and clinical translation experience, as well as Revvity's cutting-edge capabilities like its automated high-throughput drug screening platform, to create an R&D carrier that integrates target validation, compound screening, antibody drug development, and mechanism research.
Chia Tai Tianqing is also actively responding to the Grand Open Innovation (GOI) program of Shanghai's Minhang District, promoting the aggregation of high-quality innovation projects, validation of key technologies, and incubation of scientific research achievements, thereby contributing to Shanghai's efforts to build a globally influential innovation hub for the pharmaceutical industry. The laboratory now serves as the core technological foundation for attracting investment to the SBP Group R&D Innovation Center, opening up its high-throughput automated experimental capabilities to innovative enterprises in the industrial chain during idle machine time.
Li Min (Senior Director of the Equipment Engineering Center and Operations & Maintenance Management Center at Chia Tai Tianqing, and Deputy General Manager of Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.):
From project initiation to delivery, the Equipment Engineering Center and the LaNova project team worked side-by-side with Revvity engineers for 320 days and nights. The scenes from equipment arrival, installation, and joint commissioning are still vivid in my memory. Openness was the positioning determined for this platform from the very beginning of its design—it not only serves Chia Tai Tianqing's own R&D but will also be open and shared with the park and the industrial chain, fulfilling the innovation responsibilities of a large enterprise. Today, the joint shared laboratory is officially unveiled, and the report card for the construction phase has been submitted. As the operational body of the joint shared laboratory, the next crucial task for the Equipment Engineering Center is to jointly operate the high-throughput automated experimental platform well, to maximize its value proposition of "high-throughput, automation, and open sharing," and to produce more results that truly serve patients.
Building a New Paradigm of "Dry-Wet Lab Loop" in AI-Powered Drug Development
As an important part of the open innovation system at the Global R&D Headquarters, the "X" in X-Lab represents both the unknown exploration in early drug R&D and the integrated innovation of interdisciplinary fields such as AI and biotechnology.
In recent years, SBP Group has continuously promoted the application of AI throughout the entire chain of drug R&D, production, and commercialization. AI-assisted drug development now covers six major technology platforms: small molecules, antibody-drug conjugates (ADCs), siRNA, OAPD® (Oral Protein Degrader), molecular glues, and tumor microenvironment (TME), supporting 25 early research stage and 37 clinical stage pipeline projects.
When AI can generate a large number of candidate molecules in a short time, how to quickly and accurately validate their biological activity and feed the data back to the model becomes the key to further improving the efficiency of AI-powered drug development. Data generation and validation capabilities centered on the "dry-wet lab loop" are becoming a core competitive barrier in AI-powered drug development. Among these, "dry lab experiments" use AI models for protein structure prediction, antibody sequence design, and virtual screening; "wet lab experiments" use automated experimental systems to complete sample preparation, functional testing, and data collection. The experimental results are then standardized and fed back to the computational end, forming a continuous optimization mechanism of "AI design—experimental validation—data feedback—model iteration".
Qin Ying (Chief Scientist of Oncology at SBP Group, Chairman and CEO of LaNova Medicines):
For pharmaceutical companies, the efficiency of early discovery of innovative drugs will directly affect the speed of pipeline advancement. Revvity has profound expertise in the fields of automated high-throughput screening and large-scale drug discovery, which is highly aligned with Chia Tai Tianqing's innovative drug R&D strategy. We look forward to taking the joint laboratory as a new starting point, translating the platform's efficiency advantages into tangible pipeline results, accelerating the R&D of innovative drugs, and allowing the latest innovative achievements to better benefit patients.
Liu Jiang (Vice President and General Manager of Greater China at Revvity):
We are very pleased to partner with Chia Tai Tianqing to build this joint laboratory. China's innovative drugs are in a critical stage of transitioning from "follow-on innovation" to "source innovation". Revvity, through the organic synergy of reagents, instruments, and software, helps clients accelerate drug R&D by improving efficiency while balancing screening throughput and data quality. Revvity has always been committed to exploring the frontiers of life sciences. It is not only a provider of solutions but also a trusted innovation partner for the upstream and downstream sectors of the industry.
Xie An, Vice President of SBP Group; Zhao Weina, Assistant Vice President of Chia Tai Tianqing; Chen Dashun, General Counsel for Asia Pacific at Revvity; and Li Yuhu, Sales Director of the Life Sciences MELD team at Revvity, jointly attended the signing, unveiling, and delivery ceremony.
![]()
![]()
A technical exchange meeting on innovative drug R&D was also held during the event. Several industry experts attended, including Researcher Chen Ming from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; Xu Ziyao, Vice President and Head of Strategy and Innovation at BioMap; and Wan Fei, Co-founder and COO of iORGANtech. They explored new paths for biopharmaceutical development from multiple dimensions, including the frontiers of innovative drug technology, AI integration practices, and experimental platform construction.
![]()
![]()
![]()
After the unveiling and exchange meeting, the attending guests visited X-Lab on-site. Everyone watched the actual operation of the automated islands and intelligent experimental platform with great interest. In addition to the tour, they engaged in in-depth discussions about the future development direction of AI-powered drug development.
![]()
![]()
About Revvity
The partner this time, Revvity, is a leading global company in the life sciences and diagnostics fields, and is a component of the US S&P 500 index. It has a mature technology system in areas such as laboratory automation, high-throughput screening, cell analysis, and scientific research informatization. Its technologies and solutions have been widely applied in many large pharmaceutical companies. The two parties will leverage Chia Tai Tianqing's profound experience in innovative drug discovery, clinical development, and production processes, combined with Revvity's technological advantages in automated system integration, high-throughput testing, and digital analysis, to advance the integration of experimental processes and technology application in X-Lab, thereby enhancing the efficiency of early antibody drug discovery and the platform's open service capabilities.
